EBGLYSS®: a schedule with Q4W maintenance dose for long-lasting disease control1
EBGLYSS® Prefilled Pen: a patient-friendly device for easy-dosing1
Grey twist-off cap.
Hidden and automatically retractable needle.
Clear base allows 360° inspection, and large flared surface area supports stable injection.
EBGLYSS® is also available in a prefilled syringe, allowing for more control over injection speed, and can be administered by a healthcare professional for patients who may have difficulty with self-injection.1
EBGLYSS® prefilled pens and prefilled syringes can be stored at room temperature (30°C) for up to 7 days, giving patients the flexibility to travel with their medication.1
▼ This medicinal product is subject to additional monitoring.
HQ-EBG-2400007
FOOTNOTES
§EBGLYSS® label covers dosing flexibility from week 16 to week 24, so in case of no response at week 16, patients can continue with Q2W dosing until week 24 if needed.1
*Long-term safety and efficacy of EBGLYSS® has been assessed up to 52 weeks (in monotherapy/ combination therapy with topical corticosteroids) in adults and adolescents in clinical trials.1
**One year refers to the medical-scientific year of exactly 52 weeks.
REFERENCES
1. EBGLYSS® (lebrikizumab). EU Summary of Product Characteristics.